For a complete look at our 2019 performance, our earnings press
release is located here.
Since 2013, we have consistently demonstrated our ability to deliver
on our commitments and 2019 was no exception, as we delivered our
fifth consecutive year of double-digit adjusted earnings per share growth.
Our strong financial performance supports our mission to discover
and develop a consistent stream of innovative new medicines and drive
a remarkable impact for patients.
We are on track for continued growth in 2020 with our adjusted
earnings per share outlook that exceeds analyst expectations.
AbbVie has a diverse and rich pipeline that ensures we will continue
to be able to positively impact the patients we serve and ensure
growth over the long term. Over the past 7 years, our pipeline has
produced important new therapies that advance treatment options for
critical medical conditions.
We continue to invest in transformative science to fuel our pipeline
of innovative treatments for patients across several key therapeutic
areas. Learn more about our pipeline here.
The combination of our innovation and commercial execution has
resulted in a portfolio of new and differentiated medicines that
benefit millions of patients. Revenues from products launched since
inception have been steadily increasing each year and in 2019,
revenues from those products grew to $9 billion.
A strong and growing dividend is an important hallmark of our
investment identity. In 2019, we increased our quarterly dividend by
10.3 percent. Since 2013, our quarterly dividend has nearly tripled
from $0.40 to $1.18 per share.
For Investor and Media Use Only—Not For Promotional Use